CL2017002354A1 - Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. - Google Patents

Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.

Info

Publication number
CL2017002354A1
CL2017002354A1 CL2017002354A CL2017002354A CL2017002354A1 CL 2017002354 A1 CL2017002354 A1 CL 2017002354A1 CL 2017002354 A CL2017002354 A CL 2017002354A CL 2017002354 A CL2017002354 A CL 2017002354A CL 2017002354 A1 CL2017002354 A1 CL 2017002354A1
Authority
CL
Chile
Prior art keywords
activity
compounds derived
bicyclic heteroaryls
phd inhibitors
heteroaryls fused
Prior art date
Application number
CL2017002354A
Other languages
English (en)
Spanish (es)
Inventor
Richard Davenport
Susanne Wright
Saleh Ahmed
Gregory Barker
Hannan Canning
David Harrison
Kerry Jenkins
David Livermore
Natasha Kinsella
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2017002354A1 publication Critical patent/CL2017002354A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2017002354A 2015-03-18 2017-09-15 Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. CL2017002354A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504565.1A GB201504565D0 (en) 2015-03-18 2015-03-18 Novel compounds

Publications (1)

Publication Number Publication Date
CL2017002354A1 true CL2017002354A1 (es) 2018-05-04

Family

ID=53051992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002354A CL2017002354A1 (es) 2015-03-18 2017-09-15 Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.

Country Status (31)

Country Link
US (1) US10287286B2 (enExample)
EP (1) EP3271357B1 (enExample)
JP (1) JP6726681B2 (enExample)
KR (1) KR102609431B1 (enExample)
CN (1) CN107531698B (enExample)
AU (1) AU2016234209B2 (enExample)
BR (1) BR112017019653B1 (enExample)
CA (1) CA2979024C (enExample)
CL (1) CL2017002354A1 (enExample)
CO (1) CO2017009353A2 (enExample)
CR (1) CR20170468A (enExample)
DK (1) DK3271357T3 (enExample)
DO (1) DOP2017000209A (enExample)
EA (1) EA035739B1 (enExample)
EC (1) ECSP17069696A (enExample)
ES (1) ES2774052T3 (enExample)
GB (1) GB201504565D0 (enExample)
GE (1) GEP20207095B (enExample)
HU (1) HUE047918T2 (enExample)
IL (1) IL254277B (enExample)
MX (1) MX2017011902A (enExample)
MY (1) MY194873A (enExample)
NZ (1) NZ735631A (enExample)
PE (1) PE20180656A1 (enExample)
PH (1) PH12017501699B1 (enExample)
PT (1) PT3271357T (enExample)
SG (1) SG11201707280VA (enExample)
TN (1) TN2017000384A1 (enExample)
UA (1) UA123668C2 (enExample)
WO (1) WO2016148306A1 (enExample)
ZA (1) ZA201706612B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718902C2 (ru) 2016-02-24 2020-04-15 Пфайзер Инк. Производные пиразоло[1,5-а]пиразин-4-ила в качестве jak-ингибиторов
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
CN110950806A (zh) * 2019-11-14 2020-04-03 安庆博曼生物技术有限公司 四乙基氯化铵催化嘧啶环羟基氯代制备方法
JP7504822B2 (ja) * 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
US11718622B2 (en) 2020-03-16 2023-08-08 Exelixis Inc. Heterocyclic adenosine receptor antagonists
US20230322717A1 (en) * 2020-04-20 2023-10-12 Shenzhen Targetrx, Inc. Solid form of pyrazine substituted nicotinamide, and preparation and use thereof
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
IL312220A (en) 2021-10-28 2024-06-01 Insilico Medicine Ip Ltd Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof
JP2025500892A (ja) * 2021-12-17 2025-01-15 アケビア セラピューティクス インコーポレイテッド 選択的phd1阻害剤化合物、組成物、及び使用方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
DK135184A (da) * 1983-03-03 1984-10-10 Riker Laboratories Inc Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner
US4572910A (en) * 1983-03-03 1986-02-25 Riker Laboratories, Inc. Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings
JP2004502691A (ja) 2000-06-30 2004-01-29 ワイス 抗癌薬としての置換トリアゾロピリミジン
JP2010065026A (ja) 2008-08-13 2010-03-25 Ishihara Sangyo Kaisha Ltd ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤
JP2010065024A (ja) 2008-08-14 2010-03-25 Ishihara Sangyo Kaisha Ltd トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤
HRP20140705T1 (hr) * 2009-07-17 2014-09-12 Japan Tobacco, Inc. Spoj triazolopiridina i njegovo djelovanje kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
US20150239889A1 (en) 2012-08-23 2015-08-27 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compound

Also Published As

Publication number Publication date
CA2979024A1 (en) 2016-09-22
DK3271357T3 (da) 2020-02-17
CR20170468A (es) 2018-04-27
HK1249512A1 (en) 2018-11-02
SG11201707280VA (en) 2017-10-30
PE20180656A1 (es) 2018-04-17
EP3271357A1 (en) 2018-01-24
ZA201706612B (en) 2019-01-30
UA123668C2 (uk) 2021-05-12
EP3271357B1 (en) 2019-11-27
CN107531698A (zh) 2018-01-02
CN107531698B (zh) 2024-08-13
MX2017011902A (es) 2017-12-15
BR112017019653B1 (pt) 2023-10-03
NZ735631A (en) 2023-07-28
GB201504565D0 (en) 2015-05-06
DOP2017000209A (es) 2017-10-15
HUE047918T2 (hu) 2020-05-28
PH12017501699A1 (en) 2018-03-12
EA201792057A1 (ru) 2018-04-30
CA2979024C (en) 2024-02-20
CO2017009353A2 (es) 2017-11-30
TN2017000384A1 (en) 2019-01-16
IL254277A0 (en) 2017-10-31
IL254277B (en) 2020-10-29
BR112017019653A2 (pt) 2018-05-15
AU2016234209A1 (en) 2017-10-12
AU2016234209B2 (en) 2020-08-27
JP2018512408A (ja) 2018-05-17
WO2016148306A1 (en) 2016-09-22
US20180072714A1 (en) 2018-03-15
US10287286B2 (en) 2019-05-14
KR102609431B1 (ko) 2023-12-04
GEP20207095B (en) 2020-04-10
MY194873A (en) 2022-12-21
EA035739B1 (ru) 2020-08-03
ES2774052T3 (es) 2020-07-16
PT3271357T (pt) 2020-02-21
KR20170129874A (ko) 2017-11-27
JP6726681B2 (ja) 2020-07-22
ECSP17069696A (es) 2018-02-28
PH12017501699B1 (en) 2023-06-30

Similar Documents

Publication Publication Date Title
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
CR20150371A (es) Inhibidores de prmt5 y sus usos
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
SV2017005514A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
ECSP16074478A (es) Compuestos novedosos
MX381707B (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CL2016001287A1 (es) Benzamidas sustituidas y procedimiento para su uso
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY37288A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY35535A (es) ?Derivados de fenil sulfonamidas?.
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
UY35536A (es) ?derivados de sulfonamida?.
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
ECSP18056196A (es) Derivados de indano